Latest news with #ShilpaMedicare
&w=3840&q=100)
Business Standard
16-07-2025
- Business
- Business Standard
Why did Shilpa Medicare share jump 5% in trade today? top details here
Shilpa Medicare share price: Pharmaceutical company Shilpa Medicare share price was in demand on Wednesday, July 16, 2025, with the scrip rising up to 4.99 per cent to hit an intraday high of ₹939.10 per share. Around 1:30 PM, Shilpa Medicare share price was trading 4.93 per cent higher at ₹938.50. By comparison, BSE Sensex was trading 0.08 per cent lower at 82,640.01 levels. CATCH STOCK MARKET LIVE UPDATES TODAY Why did Shilpa Medicare share price rise in trade today? Shilpa Medicare share price gained in trade after the company announced a positive regulatory update from the US health regulator, United States Food and Drug Administration (USFDA). The pharma firm said its Unit VI at Dabaspet, Bengaluru received an Establishment Inspection Report (EIR) with a 'Voluntary Action Indicated' (VAI) classification from the USFDA. The EIR followed a Good Manufacturing Practices (GMP) inspection conducted between October 24-30, 2024. In an exchange filing, Shilpa Medicare said, 'This is to inform you that Shilpa Medicare Limited, Unit VI, Dabaspet, Bengaluru, Karnataka, India has received EIR with VAI (Voluntary Action Indicated) classification, from USFDA, for the GMP inspection which was conducted from October 24 – 30, 2024.' The unit is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms including Oral Dissolving Films and Transdermal Systems. Meanwhile, the unit already holds approvals from key global regulators, including EMA (Europe), MHRA (UK), SFDA (Saudi Arabia), and TGA (Australia). It currently supplies oral film products to the US and other markets, while filings for transdermal products have been made in Europe. Shilpa Medicare Q4 results Shilpa Medicare reported a mixed set of numbers in Q4FY25. While revenue from operations grew 13.3 per cent year-on-year (Y-o-Y) to ₹330.80 crore and earnings before interest, tax, depreciation and amortisation (Ebitda) rose 15 per cent to ₹84 crore, net profit (PAT) declined 40.8 per cent to ₹14.51 crore. About Shilpa Medicare Shilpa Medicare Limited is a global pharmaceutical company with a strong presence in regulated markets such as the USA, Europe, and Japan. The company specialises in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished dosage formulations, with a particular focus on oncology. Its product range includes tablets, capsules, injectables, and transdermal patches, all manufactured to meet international quality standards. Additionally, Shilpa Medicare provides end-to-end Contract Development and Manufacturing Organisation (CDMO) services, catering to a wide spectrum of pharmaceutical needs. Beyond its core offerings, the company is actively investing in research and development, focusing on novel drug delivery systems and expanding into emerging therapy areas, including biotech products. The market capitalisation of Shilpa Medicare is ₹9,177.68 crore, according to BSE. The company falls under the BSE SmallCap category.
Business Standard
16-07-2025
- Business
- Business Standard
Shilpa Medicare gains as unit VI gets USFDA EIR with VAI classification
Shilpa Medicare added 2.94% to Rs 920.70 after the company announced that its Unit VI facility in Dabaspet, Bengaluru, Karnataka, has received EIR with VAI (Voluntary Action Indicated) classification from USFDA, for the GMP inspection. The good manufacturing practice (GMP) inspection was conducted from 24 October 2024 to 30 October 2024. This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms - oral dissolving films and transdermal systems. The Unit is already approved by EMA, Europe; MHRA, UK; SFDA, Saudi and TGA, Australia. This Unit is currently supplying Oral Film products to US and other markets. Transdermal products have been filed in the European market. Shilpa Medicare is a manufacturer of API, formulation, and development services. Shilpa Medicare (SML) started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka, India. The company's consolidated net profit fell 40.77% to Rs 14.51 crore, while revenue from operations rose 13.40% to Rs 330.80 crore in Q4 FY25 over Q4 FY24.
Business Standard
16-07-2025
- Business
- Business Standard
Shilpa Medicare's Unit VI clears USFDA inspection
Shilpa Medicare announced that its Unit VI, Dabaspet, Bengaluru, has received EIR with VAI (Voluntary Action Indicated) classification, from USFDA, for the GMP inspection which was conducted from 24-30 October 2024. This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms - Oral Dissolving Films and Transdermal Systems. The Unit is already approved by EMA, Europe; MHRA, UK; SFDA, Saudi and TGA, Australia. This Unit is currently supplying Oral Film products to US and other markets. Transdermal products have been filed in the European market.
Business Upturn
16-07-2025
- Business
- Business Upturn
Shilpa Medicare shares jump nearly 5% after USFDA issues EIR with VAI for Bengaluru unit
By Aditya Bhagchandani Published on July 16, 2025, 10:11 IST Shares of Shilpa Medicare Ltd surged nearly 5% on Wednesday, July 16, trading at ₹934.95 on NSE at 10:09 AM — up ₹42.45 from the previous close of ₹892.50 — after the company announced that its Bengaluru facility received an Establishment Inspection Report (EIR) with VAI (Voluntary Action Indicated) classification from the US Food and Drug Administration (USFDA). The stock touched a day's high of ₹937.00 and a low of ₹887.00, within its 52-week range of ₹555.00–₹1,000.00. At this level, the company's market capitalization stood at around ₹91.38 billion, with a P/E ratio of 116.29 and average daily trading volume of about 181,900 shares. USFDA inspection update On July 16, Shilpa Medicare informed exchanges that its Unit VI at Dabaspet, Bengaluru received an EIR from the USFDA, marking the closure of the GMP inspection conducted between October 24–30, 2024, with a VAI classification. The unit manufactures, packages, tests, stores, and distributes Oral Dissolving Films and Transdermal Systems, with approvals already in place from EMA (Europe), MHRA (UK), SFDA (Saudi Arabia), and TGA (Australia). It is currently supplying oral film products to the US and other markets, and transdermal products have been filed for approval in Europe. About the company Shilpa Medicare is a specialty pharmaceutical company focused on complex generics, advanced drug delivery systems, and oncology formulations. The positive USFDA outcome boosts investor confidence in its regulatory compliance and growth potential in regulated markets. Investor sentiment turned upbeat today as the inspection outcome reinforced Shilpa's standing as a trusted supplier to global markets, driving the stock to the top gainer list on NSE. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. The author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Standard
10-07-2025
- Business
- Business Standard
Shilpa Medicare gains on receiving SFDA GMP certification for Bengaluru facility
Shilpa Medicare rose 1.73% to Rs 862 after the company announced that its Unit VI facility in Dabaspet, Bengaluru, Karnataka, has received Good Manufacturing Practice (GMP) certification from the Saudi Food and Drug Authority (SFDA). The certification follows an on-site inspection conducted from 18 February to 20 February 2025. It was a full GMP inspection of the entire facility, with a specific focus on the Ondansetron Oral Film drug product. Notably, the inspection concluded with zero observations. Shilpa Medicares Unit VI is engaged in the manufacturing, testing, storage, and release of finished dosage forms, specifically oral films and transdermal patches. The facility currently supplies oral films to markets including the United States, Australia, and other emerging countries.
